Calcipotriol/Betamethasone 0.005 %/ 0.064 %Topical Suspension Glenmark 50 μg/0.5 mg Topical suspension
PDF Leaflet Revision Date: 8 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Topical treatment of psoriasis vulgaris in patients 18 years and older.
Dosage (summary)
Apply once daily to affected areas for up to 4 weeks; max 15 g/day, 100 g/week.
Special Populations
- Severe hepatic disorder
- Severe renal insufficiency
Pregnancy & Breastfeeding
Contraindicated in pregnancy; caution in breastfeeding.
Contraindications
- Hypersensitivity to components
- Erythrodermic and pustular psoriasis
- Disorders of calcium metabolism
- Viral, fungal, bacterial infections
- Severe hepatic or renal insufficiency
Common side effects
- Pruritus
- Burning sensation
- Skin irritation
- Hypercalcaemia
Counselling Points
- Wash hands after application
- Avoid contact with eyes
- Do not use on face or groin
- Limit sun exposure during treatment
Serious warnings
- Risk of HPA axis suppression
- Potential for Cushingu2019s syndrome
- Avoid use on sensitive areas
Important Disclaimer
The Calcipotriol/Betamethasone 0.005 %/ 0.064 %Topical Suspension Glenmark 50 μg/0.5 mg Topical suspension professional information leaflet below is the property of Glenmark Pharmaceuticals South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
